Responsible Care
07-dec-2009
Treatment of Venous Thromboembolism (VTE)
Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE
Lees meer over de EINSTEIN studieresultaten.
Treatment of Venous Thromboembolism (VTE)
Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE
Voeg toe aan favorieten
E-mail deze pagina
Zoeken
Uitgebreid zoeken 
Video
Publicaties
Externe links
Kalender